Skip to main content
. 2016 Dec 15;4(2):e317. doi: 10.1212/NXI.0000000000000317

Figure 1. Aquaporin-4 (AQP4) antibody (Ab) serum levels, CD19+ cell counts, and clinical parameters during rituximab (RTX) treatment.

Figure 1

(A–G) Relationship among AQP4-Ab serum levels, CD19+ B cell percentage, Expanded Disability Status Scale (EDSS) score, relapses, and treatments in 7 patients with neuromyelitis optica. Patient follow-up was analyzed since the first RTX infusion (month 1). AQP4-Ab titers were expressed as the corresponding dilution factor.